トセラニブ
トセラニブ 物理性質
- 融点 :
- >133°C (dec.)
- 沸点 :
- 596.8±50.0 °C(Predicted)
- 比重(密度) :
- 1.293
- 貯蔵温度 :
- room temp
- 溶解性:
- DMSO（微量、加温）、メタノール（ごく微量、加温）
- 外見 :
- 粉
- 酸解離定数(Pka):
- 11.70±0.20(Predicted)
- 色:
- 黄色からオレンジ
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-4912 |
トセラニブ
Toceranib |
356068-94-5 |
250mg |
￥34200 |
2018-12-26 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-4912 |
トセラニブ
Toceranib |
356068-94-5 |
1g |
￥84600 |
2018-12-26 |
購入 |
|
Sigma-Aldrich Japan
|
PZ0338 |
≥98% (HPLC)
Toceranib ≥98% (HPLC) |
356068-94-5 |
5mg |
￥21000 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
PZ0338 |
≥98% (HPLC)
Toceranib ≥98% (HPLC) |
356068-94-5 |
25mg |
￥65500 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TOC3909 |
Toceranib |
356068-94-5 |
10mg |
￥72000 |
2018-12-26 |
購入 |
トセラニブ 化学特性,用途語,生産方法
用途
強力な ATP 競合的 PDGFR 及び VEGFR 阻害剤です（Ki=5 nmol/l（PDGFR）, 6 nmol/l（VEGFR））。
効能
抗悪性腫瘍薬 (獣医薬), 血管新生阻害薬, 受容体チロシンキナーゼ阻害薬
使用
Toceranib is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed m
ammary carcinomas, soft tissue sarcomas, and multiple myeloma.
Biochem/physiol Actions
Toceranib (SU11654) is a protein tyrosine kinase inhibitor that selectively targets stem cell factor receptor c-kit, including all forms of mutant Kit, as well as PDGFR and VEGFR. Toceranib exhibited Ki values of 5 nM for PDGFR and 6 nM for VEGFR. Toceranib phosphate is approved for use in mast cell cancer in dogs.
トセラニブ 上流と下流の製品情報
原材料
準備製品
トセラニブ 生産企業
Global( 111)Suppliers
356068-94-5(トセラニブ)キーワード:
- 356068-94-5
- (Z)-5-(5-Fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidenemethyl)-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide
- SU-11654
- Toceranib
- (Z)-5-[(5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
- 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylideneMethyl)-2,4-diMethyl-1H-pyrrole-3-carboxylic Acid (2-(Pyrrolidin-1-yl)ethyl)aMide
- 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxaMide
- PHA 291639
- 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylideneMethyl)-2,4-diMethyl-1H-pyrrole-3-carboxylic Acid (2-(Pyrrolidin-1-yl-d8)ethyl)aMide
- 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-N-[2-(1-pyrrolidinyl-d8)ethyl]-1H-pyrrole-3-carboxaMide
- Toceranib-d8
- Toceranib (PHA 291639, SU 11654)
- Toceranib,PHA-291639
- 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrol-3-carboxamide
- Toceranib(SU 11654
- TOCERANIB;SU 11654;PHA 291639
- (Z)-5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-p
- 5-HYDROXY-2-(4-HYDROXY-3-METHOXYPHENYL)-7-METHOXY-4H-CHROMEN-4-ONE
- 1H-Pyrrole-3-carboxaMide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-N-[2-(1-pyrrolidinyl)ethyl]-
- CS-1158
- SU 11654; PHA 291639; SU11654; SU-11654; PHA-291639; PHA291639
- Toceranib free base
- Toceranib
DISCONTINUED
- (Z)-5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrole-3-carboxamide
- トセラニブ
- 5-{[(3Z)-5-フルオロ-2-オキソ-2,3-ジヒドロ-1H-インドール-3-イリデン]メチル}-2,4-ジメチル-N-[2-(ピロリジン-1-イル)エチル]-1H-ピロール-3-カルボキサミド
- N-[2-(ピロリジン-1-イル)エチル]-5-[(Z)-(2,3-ジヒドロ-2-オキソ-5-フルオロ-1H-インドール-3-イリデン)メチル]-2,4-ジメチル-1H-ピロール-3-カルボアミド